Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2010 / Cilt: 20 - Sayı: 4

Kanser tedavisinin geç yan etkileri

Late side effects of cancer therapy

Pages
250–261
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

By preventing sequelae formation with early treatment, quality of life and long term survival can be improved.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In cancer treatment, control of advanced stage disease and cure chances are increased after the introduction of new agents and combined treatments.
📊
Key Findings & Data:Late side effects can be described as the effects that have not been recovering after treatment or developing after completion of treatment.
💡
Conclusion & Impact:By preventing sequelae formation with early treatment, quality of life and long term survival can be improved.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In cancer treatment, control of advanced stage disease and cure chances are increased after the introduction of new agents and combined treatments. Late side effects can be described as the effects that have not been recovering after treatment or developing after completion of treatment. Nowadays, patients who achieve long term cure are increasing therefore, thus many late side effects are more evident. These patients should be evaluated by a multidisciplinary team. Detection and early diagnosis programs should be performed to cancer survivors lifelong. In this rapidly growing population, we need guidelines that follow and describe late side effects objectively about cancer and cancer treatment. In this way, complications of cancer treatment can be detected earlier. By preventing sequelae formation with early treatment, quality of life and long term survival can be improved.

Özet

Kanser tedavisinde yeni ajanlar ve eş zamanlı tedaviler ile ileri evrelerde dahi hastalık kontrol edilmekte ve kür şansı artmaktadır. Geç yan etkiler tedavi sonrası geçmeyen veya tedavi tamamlanmasından sonra ortaya çıkan etkiler olarak tanımlanır. Günümüzde tedavi sonrası uzun dönem kür elde edilen hasta sayısının artması ile çok sayıda geç yan etki daha fazla dikkat çekmektedir. Bu hastalar multidisipliner bir ekip tarafından takip edilmelidir. Hastalara ömür boyu sürecek tarama ve erken tanı programları uygulanmalıdır. Bu hızla büyüyen grupta, kanser ve kanser tedavisinin takibi ve geç yan etkilerini objektif olarak ortaya koyan kılavuzlara ihtiyacımız vardır. Böylelikle kanser tedavisi komplikasyonlarını erken tespit edebilir, erken tedavi ile sekel oluşumunu engelleyerek hastaların hayat kalitesini ve uzun dönem sağkalımlarını olumlu yönde etkileyebiliriz.

🔖

Cite This Article

DEMİRCİ, U., BENEKLİ, M., BÜYÜKBERBER, S., COŞKUN, U. (2010). Kanser tedavisinin geç yan etkileri. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 20 - Sayı: 4, 250–261. https://ajindex.com/articles/323075

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. van Dalen EC, van der Pal HJ, Bakker PJ, et al. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: Asystematic review. Eur J Cancer 40: 643-652, 2004
  2. Carver JR, Shapiro CL, Ng A, et al. ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25: 3991-4008, 2007
  3. Ries LA, Percy CL, Berin GR. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975–1995. In: SEER pediatric monograph. Ries LA, Smith M, Gurray JA et al. NIH publication no: 99-464+9, MD National Cancer Institute; Bethesda, 1999, 1-5
  4. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. JAMA 290: 1583-1592, 2003
  5. Oeffinger KC, Eshelman DA, Tomlinson GE, et al. Grading of late effects in young adult survivors of childhood cancer followed in an ambulatory adult setting. Cancer 88: 1687-1695, 2000
  6. Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors CA Cancer J Clin 54: 208-236, 2004
  7. Stevens MC, Mahler H, Parkes. The health status of adult survivors of cancer childhood. Eur J Cancer 34: 694-698, 1998
  8. Dickerman JD. The late effects of childhood cancer therapy. Pediatrics 119: 554-568, 2007
  9. Atasoy BM, Unsal DK, Dincbas FO, et al. The results of questionnaire on assessing and reporting of side effects in Turkey: “Turkish Oncology Group (TOG) Early- Late Side Effects Working Party” study. Turkish Journal of Cancer 22: 13-19, 2007
  10. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 22: 4979-4990, 2004
  11. Ganz PA, Hussey MA, Moinpour CM, et al. Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol s8897. J Clin Oncol 26: 1223-30, 2008
  12. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20: 3484-3494, 2008
  13. Hudson MM, Tyc VL, Srivastava DK, et al. Multi-